14 Reconciliation of Non-GAAP Measures For an explanation of Endo’s reasons for using non-GAAP measures, see Endo’s Current Report on Form 8-K filed today with the Securities and Exchange Commission Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share Guidance for the Year Ending December 31, 2012 Lower End of Range Upper End of Range Projected GAAP diluted income per common share $1.75 $1.95 Upfront and milestone-related payments to partners $0.71 $0.71 Amortization of commercial intangible assets and inventory step-up $1.87 $1.87 Acquisition and integration costs related to recent acquisitions. $0.29 $0.29 One-time payment now expected to be made to Impax Labs $0.90 $0.90 Impairment of long-lived assets $0.33 $0.33 Interest expense adjustment for ASC 470-20 and other treasury items $0.21 $0.21 Tax effect of pre-tax adjustments at the applicable tax rates and certain other expected cash tax savings as a result of recent acquisitions ($1.06) ($1.06) Diluted adjusted income per common share guidance $5.00 $5.20 The company's guidance is being issued based on certain assumptions including: •Certain of the above amounts are based on estimates and there can be no assurance that Endo will achieve these results •Includes all completed business development transactions as of May 16, 2012 ©2012 Endo Pharmaceuticals Holdings Inc. | 
